Boothbay Fund Management’s Sonnet BioTherapeutics SONN Stock Holding History

Boothbay Fund Management’s Portfolio SONN Stock Details SONN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-56,339	Closed	-$258K	–	2329
2025 Q3	$258K	Buy	+56,339	New	+$250K	﹤0.01%	1525
2023 Q2	–	Sell	-774	Closed	-$49K	–	2258
2023 Q1	$49K	Buy	+774	New	+$125K	﹤0.01%	2022

Other funds holding SONN

FAM

Formidable Asset Management Cincinnati, Ohio $629M AUM 15.56% 1-Year Est. Return

Boothbay Fund Management's SONN Position: Q4 2025 in Review

Boothbay Fund Management sold out of Sonnet BioTherapeutics (SONN) in Q4 2025, closing a stake of 56,339 shares — an estimated $258K sold.

Boothbay Fund Management first reported a position in SONN in Q1 2023 and held it in 2 quarters. The position peaked at $258K in Q3 2025. 1 fund tracked by Wall St. Rank holds SONN as of Q4 2025.

Boothbay Fund Management reported no remaining Sonnet BioTherapeutics position as of Q4 2025 after selling out during the quarter.
Boothbay Fund Management sold 56,339 Sonnet BioTherapeutics shares in Q4 2025, an estimated $258K.
Boothbay Fund Management first reported a position in Sonnet BioTherapeutics in Q1 2023 and held it in 2 quarters.
Boothbay Fund Management's Sonnet BioTherapeutics position peaked at $258K in Q3 2025.
1 fund tracked by Wall St. Rank held Sonnet BioTherapeutics as of Q4 2025.

Based on Boothbay Fund Management's 13F filing for Q4 2025, filed 17 Feb 2026.